Abbott's Exact Sciences buy, Blackstone and TPG's Hologic acquisition, and Water's BD transaction could herald a busy 2026 ...

Last week, readers were most interested in a story about the reasons behind the rapid adoption of BioMérieux's SpotFire syndromic qPCR instrument.

The US Food and Drug Administration cleared a number of molecular tests and immunoassays, as well as a clinical chemistry and a cellular deformation test.

The digital revolution is now more quickly transforming pathology lab workflows, pointing towards accelerating adoption in the coming years.

The court invalidated a patent owned by South Korean firm GXD-Bio and rejected the firm's claims that Myriad's EndoPredict breast cancer test infringed on its intellectual property.

The new financial agreements include $5 million of new term-loan proceeds to strengthen liquidity and funding for continued investment in product development.

The false negative rates do not appear out of line with the test's sensitivity figures, but issues have been raised with its workflow and the firm's marketing strategy.

Over the year multiple clinical trial readouts validated the use of MRD for multiple indications, while companies in the space began to consolidate.

NEW YORK – As 2024 closed, the US Food and Drug Administration had — much to the chagrin of clinical labs — at last made good on its decades-long promise to regulate laboratory-developed tests (LDTs), ...

NEW YORK – Fulgent Genetics announced on Monday that it has entered into a definitive agreement to acquire lab service provider StrataDx, as well as certain assets of Bako Diagnostics. Fulgent said it ...

The deal gives clinicians in PathNet's national lab network access to Valar's AI-powered Vesta diagnostic portfolio for non-muscle invasive bladder cancer.